PeerView Gastroenterology CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerview.com

subscribe
share






Elena Elez, MD, PhD - Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents


Go online to PeerView.com/NEB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How can recent advances in managing HER2-positive GI cancers be used to further improve outcomes for patients? With the validation of novel HER2-targeted agents in gastric, colorectal, and other GI malignancies, this has become the central therapeutic question—one that can be answered by a combination of evidence-based HER2 testing and the integration of modern HER2-directed therapeutics. In this activity, experts in HER-positive gastric cancer discuss the latest clinical evidence that supports the rapid integration of HER2-directed therapies across GI cancer settings. This “Seminars and Practicum” activity pairs compelling case discussion with the science that illustrates how to use innovative HER2 therapies to meaningfully improve patient outcomes—and the implication of this management model for EU and US practice. Don’t miss this exciting, informative learning opportunity! Upon completion of this activity, participants should be better able to: Incorporate guideline-recommended HER2 testing into the routine management of patients with gastric, colorectal, and other GI tract cancers; Assess key safety and efficacy evidence on recently approved and emerging HER2-targeted therapies for different populations of patients with GI cancers; Develop individualized management plans for patients with HER2-positive GI cancers that leverage biomarker testing results, the latest clinical evidence, current guideline recommendations, and relevant patient-, disease- and treatment-specific factors; and Employ appropriate strategies and best practices to monitor for, mitigate, and manage AEs related to novel therapies for HER2-positive GI cancers.


fyyd: Podcast Search Engine
share








 August 12, 2022  1h18m